Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction
K. Vaccaro, J. Allen, T. W. Whitfield, A. Maoz, S. Reeves, J. Velarde, D. Yang, N. Phan, G. W. Bell, A. N. Hata, K. Weiskopf
The paper identifies targeted therapies that enhance lung cancer vulnerability to macrophage attack when combined with anti-CD47 antibodies, showing synergy across multiple genetic mutations.
bioRxiv · Mar 3, 2023Cancer Biology